Recursion Pharmaceuticals Q4 EPS $(0.53) Misses $(0.46) Estimate, Sales $4.55M Miss $19.04M Estimate

Benzinga
02-28

Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.46) by 15.22 percent.

Recursion shares tumbled 11% in premarket.

This is a 26.19 percent decrease over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $4.55 million which missed the analyst consensus estimate of $19.04 million by 76.13 percent. This is a 58.26 percent decrease over sales of $10.89 million the same period last year.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10